Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Survival with Cemiplimab in Recurrent Cervical Cancer

2022; Massachusetts Medical Society; Volume: 386; Issue: 6 Linguagem: Inglês

10.1056/nejmoa2112187

ISSN

1533-4406

Autores

Krishnansu S. Tewari, Bradley J. Monk, Ignace Vergote, Austin Miller, Andréia Cristina de Melo, Hee‐Seung Kim, Yong Man Kim, Alla Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih‐Long Chang, Evgeniy A. Gotovkin, Shunji Takahashi, Daniella Ramone, Joanna Pikiel, Beata Maćkowiak-Matejczyk, Eva Maria Guerra Alía, Nicoletta Colombo, Yulia Makarova, Danny Rischin, Stéphanie Lheureux, Kosei Hasegawa, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Vladimir Janković, Chieh-I Chen, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin,

Tópico(s)

Bladder and Urothelial Cancer Treatments

Resumo

Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)–blocking antibody approved to treat lung and skin cancers, has been shown to have preliminary clinical activity in this population.

Referência(s)